PROCESS FOR PRODUCING INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF NEW MACROCLES AS INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27 SUCH AS ARGYRINE AND DERIVATIVES THEREOF, AND USE THEREOF OF MACROCYCLES
The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.